Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 23 articles:
HTML format
Text format



Single Articles


    September 2017
  1. MARTINEZ VG, Rubio C, Martinez-Fernandez M, Segovia C, et al
    BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1004.2017.
    PubMed     Text format     Abstract available


  2. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    PubMed     Text format     Abstract available


    August 2017
  3. KATES M, Date A, Yoshida T, Afzal U, et al
    Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.1082.2017.
    PubMed     Text format     Abstract available


  4. ZENG S, Zhu Y, Ma AH, Yu W, et al
    The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.0033.2017.
    PubMed     Text format     Abstract available


  5. WEN T, Yang Z, He L, Lin K, et al
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0882.2017.
    PubMed     Text format     Abstract available


    July 2017
  6. VANDEKERKHOVE GR, Todenhofer T, Annala M, Struss WJ, et al
    <span style="font-weight: 400;">Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer</span>.
    Clin Cancer Res. 2017 Jul 31. pii: clincanres.1140.2017.
    PubMed     Text format     Abstract available


    April 2017
  7. YANG L, Taylor J, Eustace A, Irlam J, et al
    A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High Risk Bladder Cancer Patients.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0038.2017.
    PubMed     Text format     Abstract available


    February 2017
  8. SIN ML, Mach KE, Sinha R, Wu F, et al
    Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.2610.2016.
    PubMed     Text format     Abstract available


    November 2016
  9. INMAN BA, Longo TA, Ramalingam S, Harrison MR, et al
    Atezolizumab: a PD-L1 blocking antibody for bladder cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1417.2016.
    PubMed     Text format     Abstract available


    August 2016
  10. DERRE L, Cesson V, Lucca I, Cerantola Y, et al
    Intravesical Bacillus Calmette Guerin combined with a cancer-vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1189.2016.
    PubMed     Text format     Abstract available


    May 2016
  11. ZHANG H, Prado K, Zhang KX, Peek EM, et al
    Biased Expression of the FOXP3Delta3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
    Clin Cancer Res. 2016 May 17. pii: clincanres.2581.2015.
    PubMed     Text format     Abstract available


    March 2016
  12. FRANTZI M, Van Kessel KE, Zwarthoff EC, Marquez M, et al
    Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study.
    Clin Cancer Res. 2016 Mar 29. pii: clincanres.2715.2015.
    PubMed     Text format     Abstract available


  13. GUIN S, Ru Y, Agarwal N, Lew CR, et al
    Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
    Clin Cancer Res. 2016;22:1274-83.
    PubMed     Text format     Abstract available


    January 2016
  14. HAYASHI T, Gust KM, Wyatt AW, Goriki A, et al
    NOT ALL NOTCH IS CREATED EQUAL: THE ONCOGENIC ROLE OF NOTCH2 IN BLADDER CANCER AND ITS IMPLICATIONS FOR TARGETED THERAPY.
    Clin Cancer Res. 2016 Jan 14. pii: clincanres.2360.2015.
    PubMed     Text format     Abstract available


    December 2015
  15. GHASEMZADEH A, Bivalacqua TJ, Hahn NM, Drake CG, et al
    New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
    Clin Cancer Res. 2015 Dec 18. pii: clincanres.1135.2015.
    PubMed     Text format     Abstract available


    November 2015
  16. NOGUCHI M, Matsumoto K, Uemura H, Arai G, et al
    An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Clin Cancer Res. 2015.
    PubMed     Text format     Abstract available


    October 2015
  17. KIM HS, Jeong CW, Kwak C, Kim HH, et al
    Pathological T0 following cisplatin-based neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a network meta-analysis.
    Clin Cancer Res. 2015 Oct 26. pii: clincanres.1208.2015.
    PubMed     Text format     Abstract available


  18. KIM J, Akbani R, Creighton CJ, Lerner SP, et al
    Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.
    Clin Cancer Res. 2015;21:4514-24.
    PubMed     Text format     Abstract available


    August 2015
  19. LEE SR, Roh YG, Kim SK, Lee JS, et al
    Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer.
    Clin Cancer Res. 2015 Aug 12. pii: clincanres.2680.2014.
    PubMed     Text format     Abstract available


    March 2015
  20. DRONCA RS, Dong H
    Immunomodulatory antibody therapy of cancer: the closer, the better.
    Clin Cancer Res. 2015;21:944-6.
    PubMed     Text format     Abstract available


  21. MANGSBO SM, Broos S, Fletcher E, Veitonmaki N, et al
    The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
    Clin Cancer Res. 2015;21:1115-26.
    PubMed     Text format     Abstract available


    January 2015
  22. SVATEK RS, Zhao XR, Morales EE, Jha MK, et al
    Sequential intravesical mitomycin plus Bacillus Calmette-Guerin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.
    Clin Cancer Res. 2015;21:303-11.
    PubMed     Text format     Abstract available


  23. SHAPIRO GI, Kwak E, Dezube BJ, Yule M, et al
    First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Clin Cancer Res. 2015;21:87-97.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: